Edit
PsiOxus Therapeutics
http://www.psioxus.com/Last activity: 25.06.2026
Active - Reference to Akamis Bio
PsiOxus aims to be the world’s leading company in tumour re-programming, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage oncology company pioneering systemic immune oncology products that drive sustained reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy.
Our validated T-SIGn® vector platform can deliver multiple transgene payloads that re-program both primary and metastatic tumors. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Find our more about us at www.psioxus.com
PsiOxus is a clinical stage oncology company pioneering systemic immune oncology products that drive sustained reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy.
Our validated T-SIGn® vector platform can deliver multiple transgene payloads that re-program both primary and metastatic tumors. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Find our more about us at www.psioxus.com
Location: United Kingdom, England, Vale of White Horse
Employees: 51-200
Total raised: $75.6M
Founded date: 2010
Investors 2
| Date | Name | Website |
| 26.03.2022 | ARCH Ventu... | archventur... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.05.2015 | Series C | $38.78M | - |
| 22.11.2012 | - | $2.71M | - |
| 09.07.2012 | Series B | $34.11M | - |
Mentions in press and media 13
| Date | Title | Description |
| 30.06.2026 | NorthLinks Bio Debuts With $34M For Broad-Spectrum Antiviral | NorthLinks Bio emerges with $34M funding from RA Capital. The clinical-stage biotech focuses on broad-spectrum antiviral preventatives. Its lead, intranasal HEX17, targets respiratory viral entry. HEX17 completed Phase 2a, demonstrating a 5... |
| 25.06.2026 | NorthLinks Bio Launches With $34 Million Financing | NorthLinks Bio announced its launch and the completion of a $34 million financing from RA Capital Management. NorthLinks Bio is a clinical-stage biotechnology company developing broad-spectrum antiviral preventive medicines for respiratory ... |
| 05.01.2023 | Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics | $30 million convertible note financing co-led by ARCH Venture Partners, Parker Institute for Cancer Immunotherapy, and Westlake Village BioPartners expands investor base to include leading US life science venture capital firms Clinic... |
| 20.12.2016 | Bristol-Myers Squibb signs exclusive worldwide license agreement with PsiOxus Therapeutics | Bristol-Myers Squibb Company and PsiOxus Therapeutics today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumours. ... |
| 19.05.2015 | Mercia participates in PsiOxus funding round | Mercia Technologies PLC (AIM: MERC, “Mercia”), a Midlands based leader in the funding and commercialisation of technology businesses in the UK, has taken part in a £25 million Series C funding round in portfolio company PsiOxus Therapeutics... |
| 19.05.2015 | PsiOxus Therapeutics Closes £25M Series C Financing | PsiOxus Therapeutics Ltd., an Oxford, UK-based oncolytic immuno-oncology company, closed a £25m Series C financing round. The round was led by founding investor Imperial Innovations with participation from current investors Invesco, SROne (... |
| 16.04.2015 | PsiOxus Therapeutics expands clinical studies for immuno-oncolytic treatment following positive response to intravenous delivery | PsiOxus Therapeutics Ltd. (PsiOxus), an Oxford, UKbased biotechnology company developing innovative oncolytic immuno-oncologytreatments for cancer, has expanded two of its on-going phase I studies using its anti-cancer treatment candidate, ... |
| 16.04.2015 | PsiOxus Therapeutics to present promising new data on novel oncolytic immunocology platform at AACR 2015 | PsiOxus Therapeutics Ltd. (PsiOxus), an oncolytic immunoncology company, has announced that it will present data highlighting the progress of its next generation “Antibody Armed EnAd” (AbEnAd) anti-cancer therapeutic platform at the America... |
| 22.11.2012 | PsiOxus Receives £1.7M from Biomedical Catalyst | PsiOxus, an Oxford, UK-based development stage biotechnology company developing novel therapeutics for cancer and other clinically unmet diseases, will receive a £1.7m grant from Biomedical Catalyst. The company intends to use the funding t... |
| 09.07.2012 | PsiOxus Therapeutics Inks $34M in Series B | LONDON, ENGLAND, PsiOxus Therapeutics announced that it has closed a Series B round of equity financing totaling POUND 22 million ($34 million). The financing round will enable PsiOxus to advance the clinical development of ColoAd1, an on... |
Show more